Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro

International Journal of Cancer

Volumn 103, Issue 1, 2003, Pages 29-37

  Bilim, Vladimir ^a   Kasahara, Takashi ^a   Hara, Noboru ^a   Takahashi, Kota ^a   Tomita, Yoshihiko ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Antisense oligonucleotide; Apoptosis; Transitional cell cancer; XIAP

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOXORUBICIN; PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CELL CYCLE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CASPASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU NICK-END LABELING; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; PROTEINS; THIONUCLEOTIDES; TRANSFECTION; TUMOR CELLS, CULTURED; UROLOGIC NEOPLASMS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 0037211252     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10776     Document Type: Article

References (31)

1. Skinner D, Lieskovsky G. Diagnosis and Management of Genitourinary Cancers. Philadelphia: Saunders, 1988.
2. Rübben H, Otto T. Local advanced or metastasized carcinoma of the urinary bladder: Current aspects of therapy. Urologe A 2001;40: 464-7.
3. WAFI/CIPI induction. Apoptosis 1997;2: 207-13.
4. WAFI/CIPI and/or p53 gene alterations. Int J Cancer 1996;68:501-5.
5. Rajcan-Separovic E, Liston P, Lefebvre C, Korneluk RG. Assignment of human inhibitor of apoptosis protein (IAP) genes xiap, hiap-1, and hiap-2 to chromosomes Xq25 and 11q22-q23 by fluorescence in situ hybridization. Genomics 1996;37:404-6.
6. Asselin E, Wang Y, Tsang BK. X-linked inhibitor of apoptosis protein activates the phosphatidylinositol 3-kinase/Akt pathway in rat granulosa cells during follicular development. Endocrinology 2001;142: 2451-7.
7. Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, Bennett F, Krajewski S, Krajewska M, Welsh K, Reed JC, Ng SC. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2000;2:235-41.
8. Erl W, Hansson GK, de Martin R, Draude G, Weber KS, Weber C. Nuclear factor-kappa B regulates induction of apoptosis and inhibitor of apoptosis protein-I expression in vascular smooth muscle cells. Circ Res 1999;84:668-77.
9. Holcik M, Yeh C, Korneluk RG, Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene 2000;19:4174-7.
10. Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, Vanderhyden B, Faught W, Fung MF, Senterman M, Korneluk RG, Tsang BK. Human ovarian cancer and cisplatin resistance: Possible role of inhibitor of apoptosis proteins. Endocrinology 2001;142:370-80.
11. Li J, Sasaki H, Sheng YL, Schneiderman D, Xiao CW, Kotsuji F, Tsang BK. Apoptosis and chemoresistance in human ovarian cancer: Is Xiap a determinant? Biol Signals Receptors 2000;9:122-30.
12. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000;60:5659-66.
13. Xiao C, Ash K, Tsang B. Nuclear factor-kappaB-mediated X-linked inhibitor of apoptosis protein expression prevents rat granulosa cells from tumor necrosis factor alpha-induced apoptosis. Endocrinology 2001;142:557-63.
14. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, Scudiero DA, Tudor G, Qui YH, Monks A, Andreeff M, Reed JC. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000;6:1796-803.
15. Bilim V, Kasahara T, Noboru H, Takahashi K, Tomita Y. Caspase involved synergistic cytotoxicity of bcl-2 antisense oligonucleotides and Adriamycin on transitional cell cancer cells. Cancer Lett 2000; 155: 191-8.
16. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000;18:1812-23.
17. Zhang HG, Huang N, Liu D, Bilbao L, Zhang X, Yang P, Zhou T, Curiel DT, Mountz JD. Gene therapy that inhibits nuclear translocation of nuclear factor kappaB results in tumor necrosis factor alpha-induced apoptosis of human synovial fibroblasts. Arthritis Rheum 2000;43:1094-105.
18. Tomita Y, Bilim V, Kawasaki T, Takahashi K, Okan I, Magnusson K. Frequent expression of Bcl-2 in renal-cell-carcinomas carrying wildtype p53. Int J Cancer 1996;66:322-5.
19. Tomita Y, Kawasaki T, Bilim V, Takeda M, Takahashi K. Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/ Apo-1 (CD95)-mediated apoptosis in renal-cell-cancer cells. Int J Cancer 1996;68:132-5.
20. Mossmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxic assays. J Immunol Methods 1983;65:55-63.
21. Holcik M, Lefebvre C, Yeh C, Chow T, Korneluk R. A new internalribosome-entry-site motif potentiates XIAP-mediated cytoprotection. Nat Cell Biol 1999;1:190-2.
22. Holcik M, Korneluk R. Functional characterization of the X-linked inhibitor of apoptosis (XIAP) internal ribosome entry site element: Role of La autoantigen in XIAP translation. Mol Cell Biol 2000;20: 4648-57.
23. Carroll P. Urothelial carcinoma: Cancers of the bladder, ureter, and renal pelvis. In: Tanagho E, McAninch J, eds. Smith's General Urology. Norwalk, CT: Appleton & Lange, 1995. 353-71.
24. Lundbeck F, Bruun E, Finnerup B, Christophersen IS. Intravesical therapy of noninvasive bladder tumors (stage Ta) with doxorubicin: Initial treatment results and the long-term course. J Urol 1988;139: 1212-3.
25. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 1999;18: 5242-51.
26. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 2001;276:10767-74.
27. Levkau B, Garton KJ, Ferri N, Kloke K, Nofer JR, Baba HA, Raines EW, Breithardt G. XIAP induces cell-cycle arrest and activates nuclear factor-kappaB: New survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res 2001;88:282-90.
28. Duggan BJ, Cotter FE. Antisense bcl-2 oligonucleotide uptake in human transitional cell carcinoma. Eur Urol 2001;40:685-95.
29. Hofer-Warbinek R, Schmid JA, Stehlik C, Binder BR, Lipp J, de Martin R. Activation of NF-kappaB by XIAP, the X chromosome- linked inhibitor of apoptosis, in endothelial cells involves TAKI. J Biol Chem 2000;275:22064-8.
30. Parsons CL, Boychuk D, Jones S, Hurst R, Callahan H. Bladder surface glycosaminoglycans: An epithelial permeability barrier. J Urol 1990;143:139-42.
31. Shimizu H, Akasaka S, Suzuki S, Akimoto M, Shimada T. Preferen tial gene transfer to BBN-induced rat bladder tumor by simple instillation of adenoviral vector. Urology 2001;57:579-84.